Biotechnology company Amyris announced on Thursday that it has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for USD12.3m from the Administration for Strategic Preparedness and Response's (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC).

The company has received the agreement to advance innovative pharmaceutical manufacturing in the United States.

Amyris says that it intends to develop up to three molecule drugs over the next two years, all of which are on the FDA drug shortage list utilising its advanced technology in organism engineering, advanced precision fermentation, synthetic chemistry, process expertise and manufacturing.

IBMSC and Amyris will jointly decide which drug targets to advance to sample production. During the agreement term, Amyris will explore partnerships with GMP-manufacturing capabilities and market access to bring fully developed drugs to market.